200 related articles for article (PubMed ID: 37561261)
1. Landscape Analysis of Generic Availability for Oncologic Drugs.
Kumar V; Wang F; Hu M; Kluetz P; Zhao L
Ther Innov Regul Sci; 2023 Nov; 57(6):1279-1286. PubMed ID: 37561261
[TBL] [Abstract][Full Text] [Related]
2. Factors that have an Impact on Abbreviated New Drug Application (ANDA) Submissions.
Wittayanukorn S; Rosenberg M; Schick A; Hu M; Wang Z; Babiskin A; Lionberger R; Zhao L
Ther Innov Regul Sci; 2020 Nov; 54(6):1372-1381. PubMed ID: 32495310
[TBL] [Abstract][Full Text] [Related]
3. Predictive Analysis of First Abbreviated New Drug Application Submission for New Chemical Entities Based on Machine Learning Methodology.
Hu M; Babiskin A; Wittayanukorn S; Schick A; Rosenberg M; Gong X; Kim MJ; Zhang L; Lionberger R; Zhao L
Clin Pharmacol Ther; 2019 Jul; 106(1):174-181. PubMed ID: 31009066
[TBL] [Abstract][Full Text] [Related]
4. Pre-ANDA strategy and Human Factors activities to de-risk pharmaceutical companies ANDA submission of drug-device combination products: case study of a formative Comparative Use Human Factors study.
Brunet-Manquat L; Combedazou A; Ahuja B; Maden A; Ramus C; Mardovina T; Frolet C
Expert Opin Drug Deliv; 2024 May; 21(5):767-778. PubMed ID: 38753579
[TBL] [Abstract][Full Text] [Related]
5. Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study.
Gupta R; Bollyky TJ; Cohen M; Ross JS; Kesselheim AS
BMJ; 2018 Mar; 360():k831. PubMed ID: 29555641
[TBL] [Abstract][Full Text] [Related]
6. Statistics on BCS classification of generic drug products approved between 2000 and 2011 in the USA.
Nair AK; Anand O; Chun N; Conner DP; Mehta MU; Nhu DT; Polli JE; Yu LX; Davit BM
AAPS J; 2012 Dec; 14(4):664-6. PubMed ID: 22718306
[TBL] [Abstract][Full Text] [Related]
7. Regulating Generic Ophthalmologic Drug Bioequivalence-Envisioning Accessibility for Patients.
Luke MC; Kozak D
J Ocul Pharmacol Ther; 2021 Apr; 37(3):157-161. PubMed ID: 33332225
[TBL] [Abstract][Full Text] [Related]
8. Modified Regulatory Pathways to Approve Generic Drugs in the US and a Systematic Review of Their Outcomes.
Kesselheim AS; Polinski JM; Fulchino LA; Isaman DL; Gagne JJ
Drugs; 2015 Apr; 75(6):633-50. PubMed ID: 25822610
[TBL] [Abstract][Full Text] [Related]
9. A pragmatic regulatory approach for complex generics through the U.S. FDA 505(j) or 505(b)(2) approval pathways.
Klein K; Borchard G; Shah VP; Flühmann B; McNeil SE; de Vlieger JSB
Ann N Y Acad Sci; 2021 Oct; 1502(1):5-13. PubMed ID: 34296458
[TBL] [Abstract][Full Text] [Related]
10. Requirements for submission of bioequivalence data; final rule. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2009 Jan; 74(11):2849-62. PubMed ID: 19385107
[TBL] [Abstract][Full Text] [Related]
11. Advances in in-vitro bioequivalence testing methods for complex ophthalmic generic products.
Renukuntla J; Palakurthi SS; Bolla PK; Clark BA; Boddu SHS; Manda P; Sockwell S; Charbe NB; Palakurthi S
Int J Pharm; 2022 Nov; 627():122209. PubMed ID: 36162609
[TBL] [Abstract][Full Text] [Related]
12. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.
Alloway RR; Vinks AA; Fukuda T; Mizuno T; King EC; Zou Y; Jiang W; Woodle ES; Tremblay S; Klawitter J; Klawitter J; Christians U
PLoS Med; 2017 Nov; 14(11):e1002428. PubMed ID: 29135993
[TBL] [Abstract][Full Text] [Related]
13. FDA's Generic Drug Program: Decreasing Time to Approval and Number of Review Cycles.
Chazin H; Woo J; Han J; Grosser S; Luan J
Ther Innov Regul Sci; 2020 Jul; 54(4):758-763. PubMed ID: 32557293
[TBL] [Abstract][Full Text] [Related]
14. Common Filing Deficiencies in Abbreviated New Drug Applications Containing Clinical Endpoint Studies.
Fermaglich LJ; Chen R; Kim CY; Chuh EE; Thomas T; Shetty D; Lee J; Young J; Fan Y
Ther Innov Regul Sci; 2019 Jan; 53(1):81-85. PubMed ID: 29719976
[TBL] [Abstract][Full Text] [Related]
15. Abbreviated New Drug Applications: Generic Drug User Fee Amendments Act Analysis of Application Quality Metrics.
Woo J; Luan JJ; Li Z; Grosser S; Peters J; Chazin H
Ther Innov Regul Sci; 2019 Sep; 53(5):696-700. PubMed ID: 30360656
[TBL] [Abstract][Full Text] [Related]
16. Scientific Considerations for the Review and Approval of First Generic Mometasone Furoate Nasal Suspension Spray in the United States from the Bioequivalence Perspective.
Liu Q; Absar M; Saluja B; Guo C; Chowdhury B; Lionberger R; Conner DP; Li BV
AAPS J; 2019 Jan; 21(2):14. PubMed ID: 30617594
[TBL] [Abstract][Full Text] [Related]
17. A New Level A Type IVIVC for the Rational Design of Clinical Trials Toward Regulatory Approval of Generic Polymeric Long-Acting Injectables.
Somayaji MR; Das D; Przekwas A
Clin Pharmacokinet; 2016 Oct; 55(10):1179-1190. PubMed ID: 27349905
[TBL] [Abstract][Full Text] [Related]
18. Biopharmaceutics classification system-based biowaivers for generic oncology drug products: case studies.
Tampal N; Mandula H; Zhang H; Li BV; Nguyen H; Conner DP
AAPS PharmSciTech; 2015 Feb; 16(1):5-9. PubMed ID: 25245330
[TBL] [Abstract][Full Text] [Related]
19. The timing of 30-month stay expirations and generic entry: A cohort study of first generics, 2013-2020.
Kannappan S; Darrow JJ; Kesselheim AS; Beall RF
Clin Transl Sci; 2021 Sep; 14(5):1917-1923. PubMed ID: 33982425
[TBL] [Abstract][Full Text] [Related]
20. Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug Administration.
Tibau A; Ocana A; Anguera G; Seruga B; Templeton AJ; Barnadas A; Amir E
JAMA Oncol; 2016 Jun; 2(6):744-50. PubMed ID: 26940233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
